Transactions by TEVA PHARMACEUTICAL IND LTD (TEVA) in the last 6 months

Announced 06/17/15

35.00M for Microchips Biotech, Inc.

Private Placement

Microchips Biotech, Inc. announced that it will receive $18,648,546 in funding on June 17, 2015. The company will issue common stock in the transaction. The transaction will include participation from five investors. The company will issue securities pursuant to exemption provided under Regulation D.
On June 18, 2015, the company amended the terms of the transaction. The company announced that it has entered in to an agreement to receive $35,000,000 in an equity funding ... round from new investor, Teva Pharmaceutical Industries Limited.
As of June 24, 2015, the company has received 18,648,546 in first tranche closing from nine investors.
Read More

TEVA's price was unchanged after the transaction was announced on 06/17/15.

Investor / Buyer

Teva Pharmaceutical Industries Limited

Announced 06/2/15

American Well Corporation

Private Placement

American Well Corporation announced that it will receive tens of millions of dollars funding from new investor, Teva Pharmaceutical Industries Limited on June 2, 2015.

TEVA's price was unchanged after the transaction was announced on 06/2/15.

Investor / Buyer

Teva Pharmaceutical Industries Limited

Announced 05/17/15

Teva Pharmaceutical Industries Limited

Merger/Acquisition

Soros Fund Management LLC sold all of its 0.6% stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the first quarter of 2015. Soros Fund Management sold all the 4.9 million shares of Teva held by it.

TEVA's price was unchanged after the transaction was announced on 05/17/15.

ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) acquired New Drug Application for Testosterone Gel from Teva Pharmaceutical Industries Limited (NYSE:TEVA) for $5 million on May 13, 2015. Upon commercialization, ANI will pay Teva up to $5 million at a rate of 5% of the consideration received by ANI as a result of commercial sale of the product.

TEVA's price was unchanged after the transaction was announced on 05/13/15.

Investor / Buyer

ANI Pharmaceuticals, Inc.

Creditor / Lender

Teva Pharmaceutical Industries Limited

Announced 04/21/15

39.64B for Mylan N.V.

Merger/Acquisition

Teva Pharmaceutical Industries Limited (NYSE:TEVA) made a proposal to acquire Mylan N.V. (NasdaqGS:MYL) for $31 billion on April 21, 2015. Teva offered $82 a share in cash and stock for Mylan. The consideration would comprise of approximately 50% cash and 50% stock. The proposal was unanimously approved by the Board of Directors of Teva. This proposal is subject to customary conditions. The transaction would not be subject to a financing condition or require a Teva stockholder ... vote. Teva’s proposal is contingent on Mylan not completing its proposed acquisition of Perrigo or any alternative transactions. In a related transaction, on April 24, 2015, Mylan N.V. made a revised offer to acquire Perrigo for $31.3 billion, the offer was rejected unanimously by Perrigo Board of Directors and as of April 25, 2015, Mylan NV announced that it will take its offer for Perrigo directly to shareholders. The deal is subject to regulatory clearances. The offer will be filed for clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 immediately and will be notified to the European Commission. The transaction is expected to be completed by year-end 2015. The Board of Directors of Mylan rejected the offer on April 27, 2015.
Teva believes the combination would be significantly accretive to non-GAAP EPS, including expected non-GAAP EPS accretion in the mid-teens in the first year, and approaching 30% by the third year. As of May 28, 2015, Teva Pharmaceutical Industries Limited acquired 1.35% stake in Mylan N.V. by paying between $69 and $71 per share. Teva Pharmaceutical Industries Ltd. increased its stake in Mylan N.V. to about 2.2 percent during the week ended May 29, 2015. Teva had accumulated around 10.5 million shares in Mylan as of June 4, 2015 according to a filing. As of June 9, 2015, Teva Pharmaceutical has upped its stake in Mylan to 2.76% from 2.46%. As on June 11, 2015, Teva Pharmaceuticals raised its stake to 3%. Teva bought 1.3 million shares on June 10, 2015. As of June 17, 2015, Teva Pharmaceuticals has increased its stake in Mylan N.V. to 4.31%. As of June 19, 2015, Teva Pharmaceuticals has increased its stake in Mylan N.V. to 4.61%. Teva would limit its holdings to less than 5% of outstanding Mylan shares prior to a Mylan shareholder's meeting. The meeting will be held early in the third quarter of 2015.
Punit Mehta, Gary Posternack, Jed Brody, Len Rosen and Jordan Bliss of Barclays and Ashish Contractor and Rupert Hill of Greenhill & Co. acted as financial advisors to Teva. David Fox, Daniel Wolf and William Sorabella of Kirkland & Ellis LLP, Tulchinsky Stern Marciano Cohen Levitski & Co, Paul Cronheim of De Brauw Blackstone Westbroek N.V. and Bas Vletter, Jelmer Kalisvaart and Ruud van Bork of Loyens & Loeff N.V. acted as legal advisors to Teva. Timothy Ingrassia of The Goldman Sachs Group, Inc. (NYSE:GS) acted as financial advisor and Mark Greene, Scott Barshay and Aaron Gruber of Cravath, Swaine & Moore LLP acted as legal advisor for Mylan. Roland Berger Strategy Consultants acted as the information agent, Lazard acted as the financial advisor and Spinath & Wakkie acted as the legal advisor for Mylan. Rein Wesseling and Fons Leijten of Stibbe N.V. acted as the legal advisor for Mylan. Joseph Frumkin, Krishna Veeraraghavan, Tim Emmerson, Ben Perry, Eric Krautheimer, Matthew Friestedt and Davis Wang of Sullivan & Cromwell LLP acted as the legal advisors for Teva. Lisa Pupo Lenihan, U.S. Magistrate Judge recommended on June 9, 2015, Kirkland & Ellis LLP should not be allowed to represent Teva Pharmaceutical Industries Limited.Read More

TEVA's price was unchanged after the transaction was announced on 04/21/15.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) entered into a definitive agreement to acquire Auspex Pharmaceuticals, Inc. (NasdaqGM:ASPX) from a group of shareholders for $3.2 billion in cash on March 29, 2015. The group of shareholders includes Thomas, McNerney & Partners, Panorama Capital, CMEA Capital, Foresite Capital Management, L.L.C. and other shareholders. Under the terms of the deal, Teva will commence a tender offer for all of the outstanding shares of ... Auspex at $101 per share in cash. Each outstanding option of Auspex shall be cancelled and converted into the right to receive cash in an amount equal to the product of total number of shares of Auspex Common Stock multiplied by excess of $101 over the exercise price. The transaction is expected to be funded with cash on hand by Teva. Following the successful completion of the tender offer, Teva will acquire all remaining shares not tendered in the tender offer through a second step merger at the same price as to be paid to stockholders tendering their shares in the tender offer. Auspex will pay a termination fee of $104 million in the event of termination of the agreement.
The consummation of the tender offer is subject to a minimum tender of one more than 50% of outstanding Auspex shares, the expiration or termination of any applicable waiting periods under applicable competition laws, and other customary conditions. The transaction has been unanimously approved by the Boards of Directors of both Teva and Auspex, and key shareholders of Auspex have entered into agreements indicating their support for the transaction. Teva expects the transaction to close in middle of 2015. Teva expects the transaction to begin contributing to revenues in 2016 with the anticipated launch of SD-809 for Huntington’s disease and to be accretive to non-GAAP EPS beginning in 2017 with minimal dilution to non-GAAP EPS in the second half of 2015 and 2016.
Goldman, Sachs & Co. acted as the exclusive financial advisor to Teva. Stuart Cable, Jared Jensen, Kingsley Taft, Brad Bugdanowitz, Lisa Haddad, Karen Spindler, Lynda Galligan, Mitzi Chang and Marta Gross. Additional support was provided by Kristin Davenport, Kirby Lewis, Lindsey Wanner, Lillian Kim and Jacqueline Mercier of Goodwin Procter LLP acted as legal advisors to Teva. J.P. Morgan Securities LLC acted as financial advisor provided a fairness opinion to Auspex. Barbara L. Borden and Rama Padmanabhan of Cooley LLP acted as legal advisor to Auspex in the deal. Dan Budwick and Monique Allaire Lyons of Pure Communications, Inc. acted as public relations advisors in the deal. Minh Van Ngo of Cravath, Swaine & Moore LLP acted as legal advisor for J.P. Morgan Securities LLC.Read More

TEVA's price was unchanged after the transaction was announced on 03/30/15.

G & W Laboratories, Inc. signed an agreement to acquire Sellersville, Pennsylvania facility from Teva Pharmaceutical Industries Limited (NYSE:TEVA) on March 2, 2015. The transaction includes the grant to G & W of exclusive rights to sell up to two additional Teva products in the U.S. under G & W's label, which Teva will continue to manufacture at its Zagreb, Croatia facility. G & W Laboratories will offer employment to all the employees located in acquire Sellersville. ... The transaction is subjected to regulatory approval and expected to complete in March or April 2015.Read More

TEVA's price was unchanged after the transaction was announced on 03/2/15.

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.